Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older
Actas Dermo-Sifiliográficas · 2026
DOI: 10.1016/j.ad.2025.104487 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Actas Dermo-Sifiliográficas, 2026. Verfasst von S Vañó-Galván und 5 weiteren Autor:innen. Beteiligte Einrichtung: Director de la Unidad de Tricología del Hospital Ramón y Cajal y de la Clínica Grupo Pedro Jaén, IRYCIS, TricoHRC, Universidad de Alcalá, Madrid, Spa…. Hauptthemen laut MEDLINE: Alopecia Areata, Janus Kinase 3, Protein Kinase Inhibitors, Janus Kinase Inhibitors. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Alopecia areata (AA) is a dermatological disease of immune origin characterized by partial or total hair loss of the scalp (alopecia totalis) or the whole body (alopecia universalis). Current therapeutic options, both topical and systemic, use nonspecific immunosuppressive or immunomodulatory management strategies. The crucial role of Janus kinases (JAK) in the pathogenesis of the disease has led to a change in the therapeutic landscape, opening new approaches in the management of this disease. Ritlecitinib, a JAK3/TEC kinase inhibitor, has recently been approved for the treatment of severe AA in patients aged 12 and older. This review analyses the mechanism of action of ritlecitinib and the evidence for its safety and efficacy profile in patients with severe AA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Director de la Unidad de Tricología del Hospital Ramón y Cajal y de la Clínica Grupo Pedro Jaén, IRYCIS, TricoHRC, Universidad de Alcalá, Madrid, Spain.
- Servicio de Dermatología del Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain.
- Servicio de Dermatología del Hospital Virgen de las Nieves Granada (Guadix) y Responsable Médico de la Clínica Dermatológica Serrano, Granada, Spain.
- Departamento Médico de Pfizer, Madrid, Spain. Electronic address: maria.fortes@pfizer.com.
- Departamento Médico de Pfizer, Madrid, Spain.
- Jefe de Servicio de Dermatología, Hospital Universitario la Fe de Valencia, Spain; Universidad de Valencia, Spain.
Förderung
- Pfizer
Zitieren
APA
Vañó-Galván, S., Figueras-Nart, I., Serrano, C., Fortes, M. P., Herrera-Lasso, V., & Botella-Estrada, R. (2026). Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older. Actas Dermo-Sifiliográficas. https://doi.org/10.1016/j.ad.2025.104487
Vancouver
Vañó-Galván S, Figueras-Nart I, Serrano C, Fortes MP, Herrera-Lasso V, Botella-Estrada R. Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older. Actas Dermo-Sifiliográficas. 2026. doi:10.1016/j.ad.2025.104487
BibTeX
@article{VaGalvn2026,
author = {Vañó-Galván, S and Figueras-Nart, I and Serrano, C and Fortes, M P and Herrera-Lasso, V and Botella-Estrada, R},
title = {Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older},
journal = {Actas Dermo-Sifiliográficas},
year = {2026},
doi = {10.1016/j.ad.2025.104487}
}
EUVIMED